Citi has started a 30-day upside catalyst on PB Fintech, predicting an 18% increase in shares, with a target price of Rs 1,925. The brokerage maintains a 'buy' rating, citing strong momentum in high loan-to-value (LTV) and customer acquisition cost (CAC) segments, particularly in retail health and protection.
The narrowing gaps between contribution margins and EBITDA margins are also seen as positive indicators for growth.
Following the announcement, PB Fintech shares experienced a significant rise, increasing over four percent, and were trading at Rs 1,680.4 on the NSE, reflecting a 3.6% increase.